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Available online 2 March 2012Sinupret® is frequently used as a herbal medicinal product to treat sinusitis, and it was assumed
that anti-inflammatory effects might contribute to its overall beneficial properties. Here, we
investigated the effects of a Sinupret® drug mixture (SIN) as well as of the novel Sinupret® dry
extract (SIN DE) with the latter containing higher concentrations of active ingredients, in an
in vivomodel of acute inflammation, the carrageenan-induced pleurisy in rats. Both SIN and SIN
DE were administered to rats orally at doses of 100 mg/kg (low dose) and 500 mg/kg (high
dose) 1 h prior to intrapleural injection of carrageenan. Althoughboth SIN and SINDE significantly
reduced the exudate volume and leukocyte numbers in the pleural exudate at the high and the
low dose 4 h after carrageenan injection, the novel SIN DE was more efficient than SIN at the
low dose, implying higher efficiency. In parallel, the novel dry extract SIN DE, but not SIN, at
500 mg/kg significantly lowered the levels of prostaglandin (PG)E2 in the exudates and reduced
the amounts of cyclooxygenase (COX)-2 protein in the lungs. Together, SIN and SIN DE exert
significant oral anti-inflammatory effects, which rationalize their therapeutic use in the manage-
ment of sinusitis and other viral/microbial nasal infections that are associatedwith inflammation.
Moreover, our results suggest that based on the higher efficiency and the accompanied reduction
of COX-2 expression and PGE2 formation, the novel dry extract SIN DEmight be superior over the
former SIN drug mixture.
© 2012 Elsevier B.V. All rights reserved.Keywords:
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Inflammatory diseases are accompanied by neutrophil in-
filtration, cytokine release (e.g., tumor necrosis factor (TNF)α
and interleukin (IL)-1β) and formation of pro-inflammatorynes;NO, nitric oxide;
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ll rights reserved.mediators (e.g., leukotrienes (LT) and prostaglandins
(PGs)). Several experimental findings have shown that these
mediators contribute to tissue damage characteristic of the
inflammatory process in vivo [1–5]. In addition, activated
neutrophils release various proteases (e.g., leukocyte elastase
or cathepsin G) and generate reactive oxygen species [6–8],
both of which destroy invading particles but also damage
cells and tissues of the host. Interference with the generation
or action of these pro-inflammatorymediators exerts beneficial
effects in a variety of inflammation models including the
carrageenan-induced pleurisy model [9,10].
Sinupret® is a herbal medicinal product composed of
Gentianae radix, Primulae flos cum calycibus, Sambuci flos,
Rumicis herba (sorrel), and Verbenae herba that is frequently
used for the treatment of acute or chronic rhinosinusitis in
716 A. Rossi et al. / Fitoterapia 83 (2012) 715–720Germany and other European countries [11]. In carrageenan-
induced paw edema studies an anti-inflammatory effect of
Sinupret® as well as one of its herbal ingredients could be
shown [12,13]. Moreover, patients with acute otitis media
daily treated three times with two tablets of Sinupret® for
ten days improved the disease state accompanied by a slight
drop of the pro-inflammatory cytokines TNFα and IL-6 levels
in the blood [14]. Based on a highly standardized dry extract
of the well-established combination of five herbal drugs, a
novel Sinupret® herbal medicinal product was developed
that contains higher concentrations of active ingredients.
Here we investigated the ability of the Sinupret® drug
mixture (SIN) and the newly developed Sinupret® dry extract
(SINDE) to suppress typical pro-inflammatory events in awell-
established and robust in vivo model of acute inflammation,
that is, the carrageenan-induced rat pleurisy, which is widely
utilized for the in vivo screening of anti-inflammatory com-
pounds [9]. Our data show that both, SIN and SIN DE are effi-
cient anti-inflammatory agents, while the novel SIN DE has
superior efficiency over the drug mixture, and it also signifi-
cantly inhibits PGE2 synthesis and cyclooxygenase (COX)-2
expression. We conclude that the newly developed dry extract
SIN DE possesses a promising pharmacological profile support-
ing its potential therapeutic application.
2. Experimental
2.1. Materials
SIN (BNO D_100) was supplied by the manufacturer. The
mixture contains pulverized drugs from Gentianae radix,
Primulae flos cum calycibus, Sambuci flos, Rumicis herba (sor-
rel), and Verbenae herba in the fixed ratio of 1:3:3:3:3. SIN DE,
a native dry extract (special extract BNO 1011), was also sup-
plied by the manufacturer. The composition of the native dry
extract SIN DE regarding the herbs is identical to that of SIN,
however, the dry extract SINDE contains higher concentrations
of active ingredients compared with SIN. SIN DE was prepared
with 59% ethanol as extracting agent (V/V) (with a final drug:
extract ratio of 4.2:1). The quality of herbal drugs (startingma-
terial) is specified according to the relevant EMA-Guidelines for
herbal medicinal products. Both, SIN and SIN DE, were manu-
factured in a validated production process according to GMP.
Comprehensive specifications and standardized production
processes guarantee high batch-to-batch consistency.
For the analysis of the SIN and of SIN DE in the pleurisy
model, the compounds were freshly (not more than 4 h
prior application) resuspended in water at room temperature
using a magnetic stirrer. Homogenous suspensions were
obtained and used for further analysis. λ-Carrageenan type
IV isolated from Gigartina aciculaire and Gigartina pistillata
was purchased from Sigma–Aldrich (Milan, Italy). 3H-PGE2
was from PerkinElmer Life Sciences (Milan, Italy) and PGE2
antibody from Sigma–Aldrich (Milan, Italy). Other reagents
and compounds used were obtained from Sigma–Aldrich
(Milan, Italy) if not stated otherwise.
2.2. Animals
Male Wistar Han rats (220–230 g, San Pietro al Natisone,
Italy) were housed in a controlled environment and standardrodent chow and water were provided ad libitum. Animal
care compliedwith Italian regulations on protection of animals
used for experimental and other scientific purpose (Ministerial
Decree 116192) as well as with the European Economic
Community regulations (Official Journal of E.C. L 358/1 12/18/
1986).
2.3. Carrageenan-induced pleurisy
Rats were divided into six groups (n=10 for each group).
SIN and the novel SIN DE (100 and 500 mg/kg, each), indo-
methacin (5 mg/kg) or vehicle (1 mL water) were given per
os 1 h before carrageenan. Rats were anaesthetized with
enflurane (4%) mixed with O2 (0.5 L/min), N2O (0.5 L/min),
and submitted to a skin incision at the level of the left sixth
intercostal space. The underlying muscle was dissected, and
saline (0.2 mL) or 1% λ-carrageenan type IV (w/v) (0.2 mL)
was injected into the pleural cavity. The skin incision was
closed with a suture, and the animals were allowed to recover.
4 h after the injection of carrageenan, the animals were killed
by inhalation of CO2. The chest was carefully opened, and the
pleural cavity was rinsed with 2 mL saline solution containing
heparin (5 U/mL). The exudates and washing solution were
removed by aspiration, and the total volume was measured.
Any exudate that was contaminated with blood was discarded.
Polymorphonuclear neutrophils (PMNs) in the exudates were
resuspended in phosphate-buffered saline (PBS) and counted
with an optical light microscope in a Burker's chamber after
vital trypan blue staining. The exudates were centrifuged at
800×g for 10 min. The amount of LTB4 and PGE2 in the super-
natant was assayed by enzyme immunoassay and radioimmu-
noassay (Cayman Chemical, Ann Arbor, MI), respectively,
according to manufacturer's protocol. TNFα and IL-1β levels
were evaluated in the supernatants by using ELISA kits (R & D
Systems,Minneapolis, USA). The results are expressed as nano-
gram per rat.
2.4. Analysis of COX-2 expression in rat lungs
At 4 h after carrageenan administration, the lungs were ho-
mogenized in a buffer containing 20 mMHEPES pH7.6, 1.5 mM
MgCl2, 400 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM dithio-
threitol, 0.5 mM phenylmethylsulfonyl fluoride, 15 μg/mL
trypsin inhibitor, 3 μg/ml pepstatin, 2 μg/mL leupeptin, 40 μM
benzamidine, 1% Nonidet P-40, 20% glycerol, and 50 mM NaF.
The homogenates were centrifuged at 10,000×g for 15 min at
4 °C, the supernatant was collected, and protein concentration
was determined by Bio-Rad protein assay (Bio-Rad Laborato-
ries, Milan, Italy). Equal amounts of protein (30 μg) were
mixed with gel loading buffer (50 mM Tris, 10% SDS, 10% glyc-
erol, 10% 2-mercaptoethanol, and 2 mg/mL bromophenol) in a
ratio of 1:1, boiled for 3 min and centrifuged at 10,000×g for
10 min. Each sample was loaded and electrophoresed on a
10% SDS–polyacrylamide gel. The proteins were transferred
onto nitrocellulose membranes. The membranes were blocked
with 0.1% PBS-Tween containing 5% non-fat dry milk. After the
blocking, the membranes were incubated with the primary
antibody for 2 h at room temperature. Rabbit monoclonal anti-
body anti-COX-2 (CaymanChemical, AnnArbor,MI)was diluted
1:500 in 0.1% PBS-Tween containing 5% non-fat dry milk. After
the incubation, the membranes were washed six times with
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ture with horseradish peroxidase-conjugated secondary anti-
body (Dako Cytomation, Glostrup, Denmark) diluted 1:1000 in
0.1% PBS-Tween containing 5% non-fat dry milk. The mem-
branes were washed and protein bands were detected by an
enhanced chemiluminescence system (GE Healthcare, Freiburg,
Germany). Densitometric analysis was performedwith a Fluor S
quantitative imaging system (Bio-Rad Laboratories,Milan, Italy).
2.5. Statistical procedures
All values in the figures and text are expressed as mean±
standard error of the mean (SEM) of n observations, where n
represents the number of animals studied. The data were ana-
lyzed by one-way ANOVA followed by Tukey HSD post-hoc
tests. A P value less than 0.05 was considered statistically
significant.
3. Results
3.1. Inhibition of exudate formation and PMN inﬁltration in
carrageenan-induced pleurisy
To assess the effectiveness of SIN and of SIN DE as anti-
inflammatory agents in vivo, the compounds were tested in
a severe model of acute inflammation, that is, pleurisy
induced by carrageenan in rats. Injection of carrageenan
into the pleural cavity of rats (vehicle group, 10 animals perPG
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Data are expressed as mean±SEM. **pb0.01; ***pb0.001 vs vehicle (Tukey test). ngroup) elicited an acute inflammatory response within 4 h
characterized by the accumulation of fluid that contained
large numbers of PMNs (Fig. 1A/B). Per os pre-treament of
rats (1 h) with 100 or 500 mg/kg SIN or SIN DE inhibited
the inflammatory response induced by intrapleural injection
of carrageenan, as demonstrated by the significant attenua-
tion of exudate formation and PMN infiltration, respectively
(Fig. 1A/B). Note that SIN DE was more efficient than SIN at
the lowdose regarding the reduction of both exudate formation
and PMN infiltration. As expected, the potent non-steroidal
anti-inflammatory drug (NSAID) indomethacin (5 mg/kg, per
os), used as reference drug, strongly suppressed the inflamma-
tory response as well (Fig. 1A/B).3.2. Analysis of eicosanoid levels in pleural exudates of
carrageenan-treated rats
The eicosanoids, i.e., PG and LT produced by the 5-
lipoxygenase and the COX pathway, respectively, are major
low molecular weight compounds that mediate numerous
pro-inflammatory events [15], and LTB4 and PGE2 were
shown to be elevated in the exudates of carrageenan-treated
rats [1,16]. SIN failed to affect PGE2 and LTB4 formation in
carrageenan-treated rats (Fig. 1C/D). When rats were pre-
treatedwith 100 mg/kg SIN DE, the levels of PGE2 were slightly
(10%) but not significantly lower compared to vehicle-treated
animals. However, at the higher dose of 500 mg/kg, SIN DE
led to a significant inhibition of PGE2 formation (30%; pb0.01;in
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(Fig. 1D). As expected, the COX inhibitor indomethacin blocked
PGE2 synthesis but LTB4 was not affected.3.3. Analysis of COX-2 expression in the lungs of
carrageenan-treated rats
The impaired PGE2 formation in rats treatedwith high-dose
SIN DE encouraged us to investigate whether the extract may
affect the protein expression of the key enzyme in PGE2 forma-
tion at inflammatory sites, namely COX-2 [15,17].Western blot
analysis of lungs of rats after carrageenan-treatment revealed
strong COX-2 protein induction in vehicle-treated animals
(Fig. 2). However, in the lungs of rats that received the high
dose of SIN DE (500mg/kg), the COX-2 protein levels were
significantly reduced by about 42% (Fig. 2B). For comparison,
also lungs of rats pre-treated with SIN were analyzed forCOX-2
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lungswere homogenized and equal amounts of protein (30 μg)were electrophoresed o
(upper panels); β-actin was analysed as control protein. Bands were analyzed by dens
*pb0.05 vs vehicle (Tukey test).COX-2 protein but, in contrast to SIN DE-treated rats, no
impaired protein levels were observed (Fig. 2A).3.4. Analysis of cytokine levels in the exudates of carrageenan-
treated rats
The release of inflammatory cytokines, such as TNFα and
IL-1β by activated PMN, represents a pivotal biochemical
event to initialize, maintain, and propagate the inflammatory
response within injured tissues [3]. Pre-treatment of rats
with 100 mg/kg SIN or SIN DE impaired the IL-1β levels by
27 and 11% (p>0.05), respectively. At the higher dose
(500 mg/kg), IL-1β was reduced by 40% (pb0.01) and 19%,
respectively (Fig. 3A). In contrast, the carrageenan-induced
elevation of TNFα was not affected by either SIN or SIN DE
(Fig. 3B). Note that indomethacin caused neither an impair-
ment of TNFα nor of IL-1β, as expected.100 mg/kg
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Here, we have assessed the efficacy of SIN drugmixture and
of the novel advanced dry extract SIN DE after per os adminis-
tration in a well-established, robust in vivo animal model of
acute inflammation, the carrageenan-induced rat pleurisy.
Both SIN and SIN DE clearly reduced the inflammatory
response, with the dry extract SIN DE being superior over the
drug mixture SIN at the low dose of 100 mg/kg. Moreover,
our results provide some insights into the biochemical mecha-
nisms. Thus, reduced COX-2 expression and accompanied
decreased generation of pro-inflammatory PGE2 may account
for the efficient anti-inflammatory effect of SIN DE, whereas
impaired IL-1β release seems to contribute to the anti-
inflammatory action of SIN drug mixture. We conclude that
SIN and SIN DE possess anti-inflammatory activity when
given orally, where the dry extract SIN DE might be superior
over SIN drug mixture, and these properties might contribute
to the well-recognized beneficial features in the treatment of
sinusitis.
Based on its secretolytic, anti-viral, and anti-bacterial prop-
erties, the Sinupret® medicinal product is commonly used as
herbal medicine to treat rhinosinusitis. Sinupret® was shown
to release toughmucus, to clear the congested nose, to alleviate
head pressure and headache, as well as to fight against both
viral and bacterial infections [11,12,18]. Moreover, anti-
inflammatory features have been proposed to contribute tothe overall beneficial properties of the Sinupret® herbalmedic-
inal product [12–14]. Our present data unambiguously confirm
such anti-inflammatory properties of the Sinupret® drug mix-
ture SIN in vivo as exudate formation in the pleural cavity and
the infiltration of pro-inflammatory PMN after carrageenan-
challenge of the rats were significantly and dose-dependently
reduced after per os treatment of the rats. Hence, for the first
time, we likewise substantiate anti-inflammatory activity
in vivo for the novel dry extract SIN DE.
α formation our data also allow to speculate about the
mechanisms underlying the anti-inflammatory action of the
extracts. The carrageenan-induced pleurisy is accompanied
by eicosanoid generation and cytokine release which are con-
sidered to be required for induction of the inflammatory re-
sponse [1–5]. Upon carrageenan challenge, the expression of
the inducible COX-2 was strongly upregulated within 4 h and
this was accompanied by a strong increase in the formation of
PGE2. Among the PGs, PGE2 plays the major role in mediating
the inflammatory response, and the anti-inflammatory effec-
tiveness of NSAIDs correlates with reduced PGE2 generation
[19]. In fact, the reference compound indomethacin, a well-
recognized NSAID that acts by inhibiting COX-1/2 [20], sup-
pressed PGE2 down to non-detectable levels, accompanied by
almost complete prevention of exudate formation and PMN in-
filtration. Note that neither LTB4 levels nor TNFα and IL-1β
release were significantly suppressed by indomethacin, sup-
porting the critical role of prostanoids, seemingly produced
by COX-2 under the experimental conditions used [17]. High-
dose SIN DE blocked COX-2 expression and at the same time
significantly impaired the PGE2 levels. Of interest, as found for
indomethacin, the levels of LTB4 and TNFα were not reduced
by the dry extract SIN DE, and only a minor decrease of IL-1β
was evident, implying that suppression of PGE2 might essen-
tially underlie the anti-inflammatory effect of SIN DE. On the
other hand, also SIN significantly reduced the exudate forma-
tion and PMN infiltration but failed to lower COX-2 expression
and PGE2 levels. It is possible that some bioactive compo-
nent(s) are enriched in SIN DE vs SIN and that they reach suffi-
cient bioactive concentrations only in the high-dose SIN DE
group. These enriched bioactive substances may be responsible
for the repression of COX-2 and PGE2. Nevertheless, SIN signif-
icantly impaired IL-1β levels, which may be an alternative
cause for the anti-inflammatory activity. In fact, in acute (4 h)
zymosan-induced rat pleurisy, polyclonal murine anti-IL-1β
serum selectively inhibited the number of neutrophils that mi-
grated to the inflamed site [21], and also pre-treatment of rats
with a human IL-1β receptor antagonist suppressed the infil-
tration of cells into the pleural cavity during acute (5 h)
carrageenan-induced pleurisy [22]. At the moment, we can
only speculate about the biochemical mechanisms that cause
IL-1β reduction by SIN and COX-2 repression by SIN DE. On
one hand, the expression of IL-1β might be affected by SIN as
is the case for glucocorticoids that block IL-1β gene transcrip-
tion involving the nuclear factor-kappaB (NFκB) pathway
[23,24]. On the other hand, SIN might interfere with post-
translational mechanisms and secretion of IL-1β. Suppression
of COX-2 protein and thus reduced PGE2 synthesis by SIN DE
may also be due to several possible mechanisms such as inter-
ference with the signalling pathway induced by carrageenan
(including the NFκB pathway) [25] or degradation of COX-2
mRNA. Finally, we would like to emphasize that interference
720 A. Rossi et al. / Fitoterapia 83 (2012) 715–720with additional pro-inflammatory key events and key mole-
cules (that have not been subject of investigation in this
study) may contribute to the anti-inflammatory actions of the
extracts, including suppression of other cytokines (e.g., IL-2,
-6, -8, -12, -23), protease secretion, reactive oxygen species for-
mation, inducible nitric oxide (NO) synthase expression, and
NO generation, as well as inhibition of histamine release.
In conclusion, both SIN and the dry extract SINDE exhibited
potent anti-inflammatory activity during carrageenan-induced
pleurisy in vivo after per os treatment of rats. These data
support the therapeutic use of Sinupret® against sinusitis, a
pathological process that has a strong inflammatory compo-
nent, and rationalize further in vitro analysis of the biochemical
and molecular mechanistic details underlying the anti-
inflammatory effects of SIN and SIN DE.
References
[1] Cuzzocrea S, Rossi A, Serraino I, Mazzon E, Di Paola R, Dugo L, et al. 5-
Lipoxygenase knockout mice exhibit a resistance to pleurisy and lung
injury caused by carrageenan. J Leukoc Biol 2003;73:739–46.
[2] Fialkow L, Wang Y, Downey GP. Reactive oxygen and nitrogen species
as signaling molecules regulating neutrophil function. Free Radic Biol
Med 2007;42:153–64.
[3] Frode TS, Souza GE, Calixto JB. The modulatory role played by TNF-alpha
and IL-1 beta in the inflammatory responses induced by carrageenan in
the mouse model of pleurisy. Cytokine 2001;13:162–8.
[4] Mazzon E, Cuzzocrea S. Role of TNF-alpha in lung tight junction alteration
in mouse model of acute lung inflammation. Respir Res 2007;8:75.
[5] Ueno A, Oh-ishi S. Critical roles for bradykinin and prostanoids in acute
inflammatory reactions: a search using experimental animal models.
Curr Drug Targets Inflamm Allergy 2002;1:363–76.
[6] Conner EM, Grisham MB. Inflammation, free radicals, and antioxidants.
Nutrition 1996;12:274–7.
[7] Krause KH, Campbell KP, Welsh MJ, Lew DP. The calcium signal and
neutrophil activation. Clin Biochem 1990;23:159–66.
[8] Parekh AB, Penner R. Store depletion and calcium influx. Physiol Rev
1997;77:901–30.
[9] Moore AR. Pleural models of inflammation: immune and nonimmune.
Methods Mol Biol 2003;225:123–8.[10] Morris CJ. Carrageenan-induced paw edema in the rat and mouse.
Methods Mol Biol 2003;225:115–21.
[11] Melzer J, Saller R, Schapowal A, Brignoli R. Systematic review of clinical
data with BNO-101 (Sinupret) in the treatment of sinusitis. Forsch
Komplementmed 2006;13:78–87.
[12] März RW, Ismail C, Popp MA. Profile and effectiveness of a phytogenic
combination preparation for treatment of sinusitis. Wien Med
Wochenschr 1999;149:202–8.
[13] Schwartner C,Michel C, Stettmaier K,WagnerH, BorsW.Marchantins and
related polyphenols from liverwort: physico-chemical studies of their
radical-scavenging properties. Free Radic Biol Med 1996;20:237–44.
[14] Chkhaidze I, Nemsadze K, Gotsadze K, Nikoleishvili E, Gordeladze G. Sys-
temic inflammatory responses in patients with acute otitis media and
the impact of treatment with Sinupret. Georgian Med News 2007:40–4.
[15] Funk CD. Prostaglandins and leukotrienes: advances in eicosanoid biol-
ogy. Science 2001;294:1871–5.
[16] Rossi A, Di Paola R, Mazzon E, Genovese T, Caminiti R, Bramanti P, et al.
Myrtucommulone from Myrtus communis exhibits potent anti-
inflammatory effectiveness in vivo. J Pharmacol Exp Ther 2009;329:
76–86.
[17] Masferrer JL, Zweifel BS, Manning PT, Hauser SD, Leahy KM, Smith WG,
et al. Selective inhibition of inducible cyclooxygenase 2 in vivo is antiin-
flammatory and nonulcerogenic. Proc Natl Acad Sci U S A 1994;91:
3228–32.
[18] Ismail C. Pharmacology of Sinupret. Recent results on the rational for
the Sinupret compound. HNO 2005;53(Suppl 1):S38–42.
[19] Rainsford KD. Anti-inflammatory drugs in the 21st century. Subcell Bio-
chem 2007;42:3–27.
[20] Ferreira SH, Moncada S, Vane JR. Indomethacin and aspirin abolish
prostaglandin release from the spleen. Nat New Biol 1971;231:237–9.
[21] Perretti M, Solito E, Parente L. Evidence that endogenous interleukin-1
is involved in leukocyte migration in acute experimental inflammation
in rats and mice. Agents Actions 1992;35:71–8.
[22] Meyers KP, Czachowski CL, Coffey JW. Effect of treatment with
interleukin-1 receptor antagonist on the development of carrageenan-
induced pleurisy in the rat. Inflammation 1993;17:121–34.
[23] Knudsen PJ, Dinarello CA, Strom TB. Glucocorticoids inhibit transcrip-
tional and post-transcriptional expression of interleukin 1 in U937
cells. J Immunol 1987;139:4129–34.
[24] Ray A, Prefontaine KE. Physical association and functional antagonism
between the p65 subunit of transcription factor NF-kappa B and the
glucocorticoid receptor. Proc Natl Acad Sci U S A 1994;91:752–6.
[25] D'Acquisto F, Ianaro A, Ialenti A, Iuvone T, Colantuoni V, Carnuccio R. Acti-
vation of nuclear transcription factor kappaB in rat carrageenan-induced
pleurisy. Eur J Pharmacol 1999;369:233–6.
